Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
Company Introduction | 上海皓元医药股份有限公司成立于2006年,位于上海张江生物医药基地,专注于小分子药物发现领域的分子砌块和工具化合物的研究开发,以及小分子药物原料药、中间体的工艺开发和生产技术改进,是一家为全球医药企业和科研机构提供从药物发现到原料药和医药中间体的规模化生产的相关产品和技术服务的高新技术企业。公司荣获了上海市“专精特新”企业、上海市小巨人企业、上海市品牌培育示范企业、上海市专利工作试点企业、浦东新区企业研发机构等多项荣誉称号。 皓元医药扎根生物医药领域,始终坚持自主科技创新,勇于挑战技术难点。历经多年的技术积累和行业沉淀,形成了包含高活性原料药(HPAPI)开发平台、多手性复杂药物技术平台、维生素D衍生物药物原料药研发平台、特色靶向药物开发平台、药物固态化学研究技术平台、分子砌块和工具化合物库开发孵化平台在内的6个核心技术平台,服务范围涵盖抗肿瘤、抗病毒、糖尿病、心脑血管、免疫系统、神经系统等治疗领域。为提升创新效能,公司不断加大对硬件设施设备的投入,配备了先进的科研设施及生产设施,建立了千克级GMP条件实验室和医药研发中心,在香港、美国均设立了商务中心。 公司坚信人才驱动创新,注重人才队伍建设,核心技术骨干团队技术水平高、创新能力强、实践经验丰富,累积申请专利百余项。 皓元医药坚持“一切为了客户,一切源于创新”的服务宗旨,密切关注全球生物医药产业的发展趋势,发挥现有的技术优势和资源优势,深耕小分子药物研发服务与产业化应用市场。目前,皓元医药与亚洲、欧洲、美洲、大洋洲等多个地区的知名医药企业、科研院所、CRO公司建立了深度合作关系,承载着来自全球3000多家合作伙伴的研发创新项目,致力于推动研发创新以改善全球病患的生存状态和生活质量。公司力争在未来成为具有国际竞争力的、世界一流的医药研发和生产服务企业,让药物研发更高效,更快上市,更早惠及人类健康。 | ||||||||||||||||||||||||
Main Business | 小分子药物发现领域的分子砌块和工具化合物的研发,以及小分子药物原料药、中间体的工艺开发和生产技术改进,为全球医药企业和科研机构提供从药物发现到原料药和医药中间体的规模化生产的相关产品和技术服务。 | ||||||||||||||||||||||||
Legal Representative | 郑保富 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 沈卫红 | ||||||||||||||||||||||||
Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
Auditors | 容诚会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 021-58338205 | ||||||||||||||||||||||||
Fax No | 021-58955996 | ||||||||||||||||||||||||
Website | www.chemexpress.com.cn | ||||||||||||||||||||||||
hy@chemexpress.com.cn | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 08/06/2021 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.850 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.150 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 16.684 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 7.586B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |